Skip to main content
SpringerLink
Log in

Medical IOP-Lowering Therapy for Neovascular Glaucoma

  • Chapter
  • First Online:
Neovascular Glaucoma

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

  • 253 Accesses

Abstract

Neovascular glaucoma requires timely and aggressive medical and surgical therapy. This chapter discusses the unique considerations for the usage of topical and oral medications. A streamlined treatment workflow and collaboration between glaucoma and retina providers can lead to optimal patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Löffler KU. Neovaskularisationsglaukom: aetiology, pathogenesis and treatment. Ophthalmologe. 2006;103(12):1057–64. https://doi.org/10.1007/s00347-006-14317.

    Article  Google Scholar 

  2. Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31(2):63–77. https://doi.org/10.1089/jop.2014.0067.

    Article  CAS  Google Scholar 

  3. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: Editrice DOGMA; 2008.

    Google Scholar 

  4. Campbell S, Hickey-Dwyer M, Harding S. Double-masked three-period crossover investigation of timolol in control of raised intraocular pressure. Eye. 1993;7:105–8. https://doi.org/10.1038/eye.1993.22.

    Article  Google Scholar 

  5. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749–60.

    Article  CAS  Google Scholar 

  6. Allen RC, Hertzmark E, Walker AM, Epstein DL. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol. 1986;101(5):535–41.

    Article  CAS  Google Scholar 

  7. Trope GE, Clark B. Beta adrenergic receptors in pigmented ciliary processes. Br J Ophthalmol. 1982;66:788–92.

    Article  CAS  Google Scholar 

  8. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine study groups 1 and 2. Ophthalmology. 2000;107(6):1171–7.

    Article  CAS  Google Scholar 

  9. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1:815–34.

    Article  CAS  Google Scholar 

  10. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337–46. https://doi.org/10.2147/tcrm.2006.2.4.337.

    Article  CAS  Google Scholar 

  11. Kampik A, Arias-Puente A, O’Brart DP, Vuori ML. European latanoprost study group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002;11:90–6.

    Article  Google Scholar 

  12. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41(Suppl 1):S19–26.

    Google Scholar 

  13. Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011;93:271–83.

    Article  CAS  Google Scholar 

  14. Lester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008;2(3):517–23.

    Google Scholar 

  15. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988;95:1217e1220.

    Article  Google Scholar 

  16. Schadlu R, Maus TL, Nau CB, Brubaker RF. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol. 1998;116(11):1441–4. https://doi.org/10.1001/archopht.116.11.1441.

    Article  CAS  Google Scholar 

  17. Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997;10(5):384–403. https://doi.org/10.2165/00002512-199710050-00006.

    Article  CAS  Google Scholar 

  18. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19(1):87–112.

    Article  CAS  Google Scholar 

  19. Lippa EA, Carlson L-E, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:495–9.

    Article  CAS  Google Scholar 

  20. Strahlman E, Tipping R, Vogel R, et al. A double-masked, randomized I-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113:1009–16.

    Article  CAS  Google Scholar 

  21. Stock JG. Sulfonamide hypersensitivity and acetazolamide. Arch Ophthalmol. 1990;108:634–5.

    Article  CAS  Google Scholar 

  22. Guedes GB, Karan A, Mayer HR, Shields MB. Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. J Ocul Pharmacol Ther. 2013;29(5):456–61. https://doi.org/10.1089/jop.2012.0123. Epub 2013 Feb 27

    Article  CAS  Google Scholar 

  23. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathway. Surv Ophthalmol. 2002;47(suppl 1):S53–64.

    Article  Google Scholar 

  24. Lindén C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999;14(5):387–98. https://doi.org/10.2165/00002512-199914050-00006.

    Article  Google Scholar 

  25. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53(Suppl1):S107–20.

    Article  Google Scholar 

  26. Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand. 2001;79(6):567–71. https://doi.org/10.1034/j.1600-0420.2001.790604.x.

    Article  CAS  Google Scholar 

  27. Reza Razeghinejad M. The effect of latanoprost on intraocular inflammation and macular Edema. Ocul Immunol Inflamm. 2019;27(2):181–8. https://doi.org/10.1080/09273948.2017.1372485.

    Article  CAS  Google Scholar 

  28. Hu J, Vu JT, Hong B, Gottlieb C. Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2020;104(8):1040–4. https://doi.org/10.1136/bjophthalmol-2019-315280. Epub 2020 Jun 12. PMID: 32532763; PMCID: PMC7577108

    Article  Google Scholar 

  29. Kumar S, Malik A, Singh M, Sood S. Efficacy of latanoprost in management of chronic angle closure glaucoma. Nepal J Ophthalmol. 2009;1(1):32–6.

    Article  CAS  Google Scholar 

  30. Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197–209.

    Article  CAS  Google Scholar 

  31. Choy M. Pharmaceutical Approval Update. P T. 2018;43(4):205–27.

    Google Scholar 

  32. Nilsson SF. The uveoscleral outflow routes. Eye (Lond). 1997;11(Pt 2):149–54. https://doi.org/10.1038/eye.1997.43.

    Article  Google Scholar 

  33. Havens SJ, Gulati V. Neovascular Glaucoma. Dev Ophthalmol. 2016;55:196–204. https://doi.org/10.1159/000431196.

    Article  Google Scholar 

  34. The Pilocarpine Paradox, Journal of Glaucoma: August 1996 – Volume 5 – Issue 4 – p 225–227.

    Google Scholar 

  35. Day AC, Nolan W, Malik AN, Viswanathan AC, Foster PJ. Pilocarpine induced acute angle closure. BMJ Case Rep. 2012:2012. https://doi.org/10.1136/bcr.01.2012.5694.

  36. Mori M, Araie M, Sakurai M, et al. Effects of pilocarpine and tropicamide on blood-aqueous barrier permeability in man. Invest Ophthalmol Vis Sci. 1992;33(2):416–23.

    CAS  Google Scholar 

  37. Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2:26. https://doi.org/10.1186/s40942-016-0051-x.

    Article  Google Scholar 

  38. Rodgin SG. Neovascular glaucoma associated with uveitis. J Am Otom Assoc. 1987;58(1):499–503.

    CAS  Google Scholar 

  39. Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci. 2014;55(5):2993–3002. Published 2014 May 6. https://doi.org/10.1167/iovs.13-12660.

    Article  CAS  Google Scholar 

  40. Costagliola C, dell’Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F. Pharmacotherapy of intraocular pressure—part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009;10(17):2859–70. https://doi.org/10.1517/14656560903300129.

    Article  CAS  Google Scholar 

  41. Macdonald MJ, Gore SM, Cullen PM, Phillips CI. Comparison of ocular hypotensive effects of acetazolamide and atenolol. Br J Ophthalmol. 1977;61(5):345–8.

    Article  CAS  Google Scholar 

  42. Loiselle AR, de Kleine E, van Dijk P, Jansonius NM. Intraocular and intracranial pressure in glaucoma patients taking acetazolamide. PLoS One. 2020;15(6):e0234690. Published 2020 Jun 18. https://doi.org/10.1371/journal.pone.0234690.

    Article  CAS  Google Scholar 

  43. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115(1):45–9. https://doi.org/10.1001/archopht.1997.01100150047008.

    Article  CAS  Google Scholar 

  44. Centofanti M, et al. Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study. Pharmacol Res. 1997;35(5):481–5.

    Article  CAS  Google Scholar 

  45. Schwenk MH, Blaustein DA, Wagner JD. The pharmacokinetics of acetazolamide during CAPD. Adv Perit Dial. 1994;10:44–6.

    CAS  Google Scholar 

  46. Zaidi FH, Kinnear PE. Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycaemic agents: comparing enzymatic with diuresis induced metabolic acidosis following intraocular surgery in diabetes. Br J Ophthalmol. 2004;88(5):714–5.

    Article  CAS  Google Scholar 

  47. Chapron DJ, Sweeny KR, Feig PU, Kramer PA. Influence of advanced age on the disposition of acetazolamide. Br J Clin Pharmacol. 1985;19:363–71.

    Article  CAS  Google Scholar 

  48. Galin MA, Binkhorst RD, Kwitko ML. Ocular dehydration. Am J Ophthalmol. 1968;66:233.

    Article  CAS  Google Scholar 

  49. Stamper R. Becker-Shaffer's diagnosis and therapy of the glaucomas. 8th ed; 2009. p. 431–4.

    Book  Google Scholar 

  50. Krupin T, Podos SM, Becker B. Alteration of intraocular pressure after third ventricle injections of osmotic agents. Am J Ophthalmol. 1973;76:948.

    Article  CAS  Google Scholar 

  51. Allen CH, Ward JD. An evidence-based approach to management of Increased Intracranial Pressure. Crit Care Clin. 1998;14(3):485–96.

    Article  CAS  Google Scholar 

  52. Crouch ER Jr, Crouch ER. Management of traumatic hyphema: therapeutic options. J Pediatr Ophthalmol Strabismus. 1999;36(5):238–50. [PubMed 10505828]

    Article  Google Scholar 

  53. Drance SM. Effect of oral glycerol on intraocular pressure in normal and glaucomatous eyes. Arch Ophthalmol. 1964;72(4):491–3. https://doi.org/10.1001/archopht.1964.00970020491009.

    Article  CAS  Google Scholar 

  54. Nissenson AR, Richard NF. Clinical Dialysis. McGraw Hill Medical Pub Division, 2005.

    Google Scholar 

  55. Virno M, et al. Oral glycerol in ophthalmology: a valuable new method for the reduction of intraocular pressure. Am J Ophthalmol. 1963;55:1133.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Science, The University of Chicago Medicine, Chicago, IL, USA

    Pathik P. Amin & Mary Qiu

Authors
  1. Pathik P. Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pathik P. Amin .

Editor information

Editors and Affiliations

  1. Ophthalmology and Visual Science, University of Chicago, Chicago, IL, USA

    Mary Qiu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Amin, P.P., Qiu, M. (2022). Medical IOP-Lowering Therapy for Neovascular Glaucoma. In: Qiu, M. (eds) Neovascular Glaucoma. Essentials in Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-031-11720-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-11720-6_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-11719-0

  • Online ISBN: 978-3-031-11720-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation